/filters:format(webp)/production/4012727/large-1726765853.png?1726765853)
QuantInsider
$RLAY took a hit this week, down about 8% with another 1.5% drop today
That post-earnings pressure and trial news are keeping the downside momentum alive
Not seeing any strong institutional options positioning to shift the tide either
Options flow is pretty sparse
Spotted a 2,236-contract December $25 call block at the ask on InsiderFinance but nothing else stands out
Just some small offsetting October call and put sweeps
No clear direction here
With the Phase 3 trial for zovegalisib starting up and the recent earnings miss, expect more headline-driven moves
For now, it’s smart to stick to defined-risk strategies and keep positions tight
Avoid going too heavy on
